Obermatt

Daewoong

KSC:003090 · KR7003090008
PharmaceuticalsMedium

360

55
Medium confidence — indicative
EV / EBIT89
Price / Owner Earnings69
Owner Earnings Yield1
Dividend Yield1
Price/Sales84
EV / Gross Profit97
Price/Book78
Return on Capital77
Cash Return on Capital40
Return on Equity84
EBIT Margin78
Gross Profitability69
Cash Conversion61
Accruals28
Owner Earnings Margin35
Sales growth33
Profit Growth63
Long-Term EPS Growth28
Reinvestment63
Price momentum10
Debt load43
Refinancing53
Debt Payback1
Liquidity74
Analyst ratings
Expectations trend
Market mood63
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Daewoong clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeKOSE
Employees1
ISINKR7003090008
Last UpdateApr 2, 2026
Themes
NutraceuticalLifestyleManufacturingPharmaceuticalSales

Description

Analysis

Middle-of-the-road

Daewoong Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 8/20 on our value-creation score: creating some value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
72
2026

All-time high

87

Mar 2026

All-time low

72

Jun 2026

Average rank

80

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
Price/Earnings
94
Price/Book
78
Dividend Yield
1
Value (overall)
75

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Daewoong with its peers
Ildong Holdings
KSC:000230
83
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Tsumura
TYO:4540
47
CountryJapan
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Pyridam Farma
JKT:PYFA
3
CountrySingapore
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
PharmGen Science
KSC:004720
74
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →